Sanofi (SNY) Return on Sales (2009 - 2026)

Sanofi (SNY) posted Return on Sales of 0.0% for Q2 2026, down 72.37% sequentially from 0.0% in Q1 2026, and little changed YoY from 0.0% in Q2 2025.

Sanofi (SNY) Return on Sales (2009 - 2026) Analysis & Trends

Sanofi has reported Return on Sales for 18 years, with the latest figure at 0.0% in Q2 2026.

Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales slipped to 0.0% in Q2 2026 per SNY's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.01% in Q4 2022 and troughed at 0.0% in Q4 2024.
A 5-year average of 0.01% and a median of 0.0% in 2025 frame the typical range for Return on Sales.
The sharpest annual moves came in 2022 and 2023: Return on Sales rose 1 bps in 2022, then decreased 1 bps in 2023.
Over 5 years, Return on Sales stood at 0.01% in 2022, then plunged by 101 bps to 0.0% in 2023, then plunged by 138 bps to 0.0% in 2024, then soared by 1307 bps to 0.0% in 2025, then slumped by 100 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Johnson & Johnson	654.14 Bn	633.38 Bn	17.26 Bn	0.00%
2	AbbVie	470.43 Bn	463.86 Bn	12.70 Bn	0.00%
3	Merck	375.33 Bn	368.19 Bn	12.21 Bn	0.00%
4	Novartis Ag	302.82 Bn	295.13 Bn	11.24 Bn	0.00%
5	Astrazeneca	257.71 Bn	252.81 Bn	12.86 Bn	0.00%
6	Amgen	237.15 Bn	223.17 Bn	7.24 Bn	0.00%
7	Gilead Sciences	183.03 Bn	179.85 Bn	6.22 Bn	-0.01%
8	Pfizer	160.08 Bn	148.39 Bn	10.94 Bn	0.00%
9	Gsk	106.10 Bn	101.93 Bn	8.24 Bn	0.00%
10	Sanofi	55.20 Bn	47.82 Bn	10.79 Bn	0.01%

Download Data